Ian Gourley

Chief Tech/Sci/R&D Officer at IMMUNOVANT, INC.

Health Technology

Consumer Services

Profile

Dr. Ian Gourley, MD, is a Member at The Royal College of Physicians and a Vice President-Clinical Development at Immunovant, Inc. Dr. Gourley was previously employed as a Head-Clinical Research Pathologist by Eli Lilly & Co., a Head-Translational Medical Science by Janssen Pharmaceuticals, Inc., and a Director-HLA Laboratory by The American Society For Histocompatibility & Immunogenetics.
He received his graduate degree from Queen's University of Belfast.

Ian Gourley active positions

Companies	Position	Start
IMMUNOVANT, INC.	Chief Tech/Sci/R&D Officer	-
The Royal College of Physicians	Corporate Officer/Principal	-

All active positions of Ian Gourley

Former positions of Ian Gourley

Companies	Position	End
ELI LILLY AND COMPANY	Corporate Officer/Principal	-
The American Society For Histocompatibility & Immunogenetics The American Society For Histocompatibility & Immunogenetics The American Society for Histocompatibility and Immunogenetics (ASHI) is a not-for-profit association of clinical and research professionals including immunologists, geneticists, molecular biologists, transplant physicians and surgeons, pathologists and technologists. As a professional society involved in histocompatibility, immunogenetics and transplantation, ASHI is dedicated to advancing the science and application of histocompatibility and immunogenetics; providing a forum for the exchange of information; and advocating the highest standards of laboratory testing in the interest of optimal patient care	Corporate Officer/Principal	-
Janssen Pharmaceuticals, Inc. Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ.	Corporate Officer/Principal	-

See the detail of Ian Gourley's experience

Training of Ian Gourley

Queen's University of Belfast

Graduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Ian Gourley's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
ELI LILLY AND COMPANY	Health Technology
IMMUNOVANT, INC.	Health Technology

Private companies	2
Janssen Pharmaceuticals, Inc. Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ.	Health Technology
The American Society For Histocompatibility & Immunogenetics The American Society For Histocompatibility & Immunogenetics The American Society for Histocompatibility and Immunogenetics (ASHI) is a not-for-profit association of clinical and research professionals including immunologists, geneticists, molecular biologists, transplant physicians and surgeons, pathologists and technologists. As a professional society involved in histocompatibility, immunogenetics and transplantation, ASHI is dedicated to advancing the science and application of histocompatibility and immunogenetics; providing a forum for the exchange of information; and advocating the highest standards of laboratory testing in the interest of optimal patient care